Login / Signup

SKF-96365 Expels Tyrosine Kinase Inhibitor-Treated CML Stem and Progenitor Cells from the HS27A Stromal Cell Niche in a RhoA-Dependent Mechanism.

Audrey DubourgThomas HarnoisLaetitia CousinBruno ConstantinNicolas Bourmeyster
Published in: Cancers (2024)
This study underscores the role of RhoA in LSC behavior under TKI treatment and suggests that SKF-96365 could remobilize quiescent CML LSCs through reactivation of the RhoA/ROCK pathway.
Keyphrases
  • chronic myeloid leukemia
  • single cell
  • bone marrow
  • advanced non small cell lung cancer
  • stem cells
  • combination therapy
  • newly diagnosed
  • neural stem cells